Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674774 | 0.98 | MAPT (0.36) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL15070197 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL1674771 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL20446705 | 0.82 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL20446680 | 0.80 | MAPT (0.36) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL1674813 | 0.80 | MAPT (0.36) | SMN1; SMN2MAPTHPGDALDH1A1LMNA | |
| SCHEMBL13721802 | 0.75 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL16886913 | 0.66 | LMNA (0.30) | MAPTALDH1A1LMNA | |
| SCHEMBL17548917 | 0.65 | — | — | |
| SCHEMBL3458804 | 0.62 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPTALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| US-5773208-A | MIXTURE WITH TETRAAZAINDENE COMPOUND | EASTMAN KODAK COMPANY (US) | 1998-06-30 | — | — | US | claimed |
| US-5691127-A | SILVER HALIDE EMULSIONS | EASTMAN KODAK COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230244134-A1 | Photographic Paper | FUJIFILM MANUFACTURING EUROPE B.V. (NL) | 2023-08-03 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-0606895-A1 | Photographic emulsions containing internally and externally modified silver halide grains | EASTMAN KODAK COMPANY (US) | 1994-07-20 | — | — | EP | disclosed |
| EP-0600564-A1 | Method of photographic processing | KODAK LIMITED (GB) | 1994-06-08 | — | — | EP | disclosed |
| US-5260184-A | Oxidatt removal by electrolysis at cathode, dialysis through semipermeable membrane, catalytic decomposition or by scavengers | EASTMAN KODAK COMPANY (US) | 1993-11-09 | — | — | US | disclosed |
| US-5256530-A | Transition metal complexes | EASTMAN KODAK COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| US-5252451-A | Comprising the transition metal complexes of a dopant and a grain surface modifier; high contrast | EASTMAN KODAK COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0469046-B1 | METHOD OF FORMING A PHOTOGRAPHIC COLOUR IMAGE | KODAK LIMITED (GB) | 1993-03-31 | — | — | EP | disclosed |
| EP-0469046-A1 | METHOD OF FORMING A PHOTOGRAPHIC COLOUR IMAGE. | KODAK LTD (GB) | 1992-02-05 | — | — | EP | disclosed |
| WO-1990013061-A1 | METHOD OF FORMING A PHOTOGRAPHIC COLOUR IMAGE | KODAK LIMITED (GB) | 1990-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | SMN1; SMN2 1778/4885MAPT 4340/4885HPGD 1096/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | SMN1; SMN2 1778/4885MAPT 4340/4885HPGD 1096/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | SMN1; SMN2 1778/4885MAPT 4340/4885HPGD 1096/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | SMN1; SMN2 1778/4885MAPT 4340/4885HPGD 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.